GlassScriptPhysician profile
Nissi S Suppogu
NPI 1801236641
$1,739.48
in general payments reported to CMS, 2019-2025
13 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $139 · 2021: $303 · 2022: $665 · 2023: $131 · 2024: $341 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $476.57 | 2021-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $228.88 | 2020-2025 | Lifevest |
| Abbott Laboratories | $180.05 | 2022-2024 | Cardiomems |
| Pfizer INC. | $161.88 | 2022-2024 | |
| Boston Scientific Corporation | $154.11 | 2024 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $137.02 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $132.60 | 2024-2025 | |
| Medtronic, INC. | $62.90 | 2024 | Corevalve Evolut R |
| Lantheus Medical Imaging, INC. | $61.02 | 2020-2021 | |
| Heartflow, INC. | $58.02 | 2024 | |
| Cardiovascular Systems INC. | $42.26 | 2022 | |
| Bardy Diagnostics, INC. | $23.48 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.69 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nissi Suppogu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.